Clinical Trials Sponsored by Brandeis University

Total 222394 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women

Oral Contraceptive | Hemostasis

Germany, Israel, Italy, Spain
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma

Exercise-induced Bronchospasm

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

BiPolar

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

Solid Tumors

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Albuterol HFA MDI in Pediatric Participants With Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN) ((PHN))

Postherpetic Neuralgia

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics

Asthma

United States, Thailand
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Australia, Belgium, Chile, Colombia, Czechia, Denmark, Hungary, Israel, Malaysia, New Zealand, Philippines, Poland, Russian Federation, South Africa, Sweden, Thailand
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women

Pharmacokinetics

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Persistent Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

Asthma

United States, Canada, Czechia, Hungary, Poland, Russian Federation, South Africa, Thailand, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

Asthma

United States, Germany, Hungary, Poland
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | COPD
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers

Pharmacokinetics

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine (FOCUS)

Migraine Prophylaxis

United States, Belgium, Czechia, Denmark, Finland, France, Germany, Italy, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

Migraine

United States, Canada, Czechia, Finland, Israel, Japan, Poland, Russian Federation, Spain
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Eosinophilic Asthma

United States, Argentina, Brazil, Canada, France, Mexico, Germany, Greece, Korea, Republic of, Peru, Romania, Russian Federation, Slovakia, Taiwan, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

First Time Use of SD-809 in Huntington Disease (First-HD)

Chorea

United States, Australia, Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Australia, Belgium, Chile, Colombia, Denmark, Hungary, Israel, Malaysia, New Zealand, Philippines, Poland, Russian Federation, South Africa, Sweden, Thailand, Argentina, Brazil, Canada, France, Mexico, Netherlands, Ge... and more
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Leukemia

Israel, United States, Australia, Belarus, Brazil, Canada, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Singapore
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Tolerability of Glatiramer Acetate (GLACIER)

Relapsing-Remitting Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Allergic Rhinitis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)

Exercise-Induced Bronchoconstriction (EIB)

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Laquinimod Phase IIa Study in Active Crohn's Disease

Crohn's Disease

Belgium, France, Israel, Italy, Netherlands, Poland, South Africa, Spain, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

Solid Tumors | Hematologic Malignancies

Netherlands
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors

Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects

Cognitive Impairment

Netherlands
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (GLOW)

Relapsing-Remitting Multiple Sclerosis

United States, Albania, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Georgia, Greece, Latvia, Macedonia, The Former Yugoslav Republic of, Mexico, Moldova, Republic of, Montenegro, Poland, Romania, Russian... and more
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects

DLBCL

Bulgaria, Estonia, France, Hungary, Italy, Latvia, Poland, Russian Federation, Spain, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Relapsing Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS) (ALSTAR OL)

Amyotrophic Lateral Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

Pain

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

Asthma | Emphysema | Chronic Obstructive Pulmonary Disease (COPD) | Chronic Bronchitis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine

Relapse Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol

Allergic Rhinitis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

Recurrent Glioblastoma Multiforme
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease (ADAGIO)

Parkinson's Disease
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

Glioblastoma Multiforme
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus (PRELUDE)

Systemic Lupus Erythematosus
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.

Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.

Parkinson's Disease

United States, Canada

Clinical Trials Sponsored by Brandeis University

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations